Biosyn   Report issue

For profit Phase 2 Phase 3
Founded: Cupertino California United States (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
2004
NCT00129532
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

biosyn Arzneimittel GmbH

Active Ingredients

Drugs in Phase 3 Trials (3)

c31g (2 trials)

procalcitonin (1 trial)

sodium selenium oxide (3 trials)

Drugs in Phase 2 Trials (1)

sélénium (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Diseases (Phase 3)

HIV Infections (Phase 3)

Sepsis (Phase 3)

Shock (Phase 2)

Shock, Septic (Phase 3)

Toxemia (Phase 3)

Ventricular Dysfunction (Phase 3)

Ventricular Dysfunction, Left (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 4